World Health Organization (WHO) experts have recommended a large-scale human trial to evaluate whether the only licensed Ebola vaccine, Ervebo, can offer protection against the Bundibugyo strain currently driving the outbreak in the Democratic Republic of Congo (DRC). The recommendation comes as the virus continues to spread, with over 4,000 confirmed cases reported so far (it-boltwise.de). Early studies suggest Ervebo, which has proven effective against the Zaire strain, may also offer some protection against Bundibugyo, a less common variant for which no approved vaccine exists.
Authorities in the DRC have confirmed that no Ebola cases were found among passengers on a riverboat placed in quarantine near Kinshasa, easing fears that the Bundibugyo strain might spread to the capital (lactualite.com). Over 200 passengers were quarantined as a precaution. This development highlights ongoing efforts to contain the outbreak and monitor potential transmission risks.
The African Centre for Disease Control (Africa CDC) has shifted to an “Active Case Search” strategy, conducting door-to-door screenings to identify more cases. Officials are also discussing possible virus mutations and considering the use of Remdesivir and Ervebo as part of treatment and prevention strategies.
